

## References

### QBRI Insights on Parkinson's Disease: A Fast-Growing Neurological Disorder.

1. Ball N, Teo WP, Chandra S, Chapman J. Parkinson's Disease, and the Environment. *Front Neurol* 2019; 10:218.
2. Balestrino R, Schapira AHV. Parkinson disease. *Eur J Neurol* 2020; 27:27-42.
3. Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. *J Parkinsons Dis.* 2018;8(s1): S3-S8. doi:10.3233/JPD-181474
4. Emamzadeh FN, Surguchov A. Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. *Front Neurosci.* 2018; 12:612. Published 2018 Aug 30. doi:10.3389/fnins.2018.00612
5. GBD 2016 Parkinsons disease collaborators ; Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology*, Vol 17, Issue 11 P939-953, Nov 2018.
6. Goldman S.M., Environmental Toxins and Parkinson's Disease. *Ann. Rev Pharmacol Toxicol.* 2014; 141-64
7. Poewe, W., Seppi, K., Tanner, C. et al. Parkinson disease. *Nat Rev Dis Primers* 3, 17013 (2017). <https://doi.org/10.1038/nrdp.2017.13>
8. Wooten GF, Currie LJ, Bovbjerg VE, et al. Are men at greater risk for Parkinson's disease than women? *Journal of Neurology, Neurosurgery & Psychiatry* 2004;75:637-639. doi.org/10.1136/jnnp.2003.020982
9. Hmila I, Vaikath NN, Majbour NK, Erskine D, Sudhakaran IP, Gupta V, Ghanem SS, Islam Z, Emara MM, Abdesselem HB, Kolatkar PR, Achappa DK, Vinardell T, El-Agnaf OMA. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity. *FEBS J.* 2022 Jan 28. doi: 10.1111/febs.16376. Epub ahead of print. PMID: 35090199.